BioMarin Pharmaceutical Inc. (BMRN) Q1 2021 Earnings Results

BioMarin Pharmaceuticals Beats on EPS, Stock Down 0.35%

BioMarin Pharmaceuticals reported a positive surprise in EPS, which indicates better-than-expected profitability. However, the stock fell slightly by 0.35%, suggesting that investors may have been looking for more comprehensive financial details or guidance. The lack of revenue information could have contributed to the muted stock reaction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.09	N/A	+38.46%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to ongoing projects. However, they did not provide specific revenue figures or guidance.

We are pleased with our EPS performance this quarter.

While we did not provide revenue figures, we remain focused on our strategic initiatives.

BioMarin Pharmaceuticals Beats on EPS, Stock Down 0.35%

Key numbers

Management commentary

BioMarin Pharmaceutical Inc.

More earnings this week

BioMarin Pharmaceuticals Beats on EPS, Stock Down 0.35%

Key numbers

Management commentary